证券代码：300254 证券简称：仟源医药 公告编号：2023-073 山西仟源医药集团股份有限公司 第五届监事会第七次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、会议召开情况 山西仟源医药集团股份有限公司（以下简称"公司"）第五届监事会第七次会 议（以下简称"本次会议"）于 2023 年 9 月 25 日（下午）召开。本次会议由监事 会主席朱海波先生主持，应到监事 3 名，实到监事 3 名。董事会秘书、证券事务代 表列席本次会议，出席会议人员对本次会议的召集、召开方式无异议。本次会议的 召集、召开符合《公司法》法律、法规等规范性文件和《公司章程》的有关规定。 二、监事会会议审议情况 出席本次会议的全体监事对本次会议的议案进行了认真审议，并以投票表决方 式审议通过《关于变更部分募集资金投资项目之药品研发项目的议案》。 经审议，监事会认为：公司变更部分募集资金投资项目之药品研发项目，有利 于提高募集资金的使用效率，符合公司的发展战略及全体股东的利益，该事项审议 程序合法、有效，符合相关法律法规的规定，我们同意公司变更部分募集资金投资 项目之 ...

证券代码：300254 证券简称：仟源医药 公告编号：2023-074 山西仟源医药集团股份有限公司 关于变更部分募集资金投资项目之药品研发项目的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 山西仟源医药集团股份有限公司（以下简称"公司"）于 2023 年 9 月 25 日 召开第五届董事会第九次会议，第五届监事会第七次会议，审议通过《关于变更 部分募集资金投资项目之药品研发项目的议案》，同意公司变更部分 2021 年度以 简易程序向特定对象发行股票募集项目之药品研究开发项目：终止 CY2021H007 项目和 CY2021H009 两个药品研究开发项目，将 CY2021H006 真实世界研究项目改 为"改进生产工艺和提升质量标准"二次开发项目；上述三个项目调整出的募集 资金研发投入 4,050 万元将投资用于 CY2021H002、CY2021H003、CY2021H004 药 品研究开发项目原募集资金投入不足部分。公司独立董事、监事会、保荐机构对 本次募集资金投资项目变更发表了相关意见，上述事项尚须提交公司股东大会审 议通过。现将相关情况公告如下： ...

（以下无正文，次页为签署页） 山西仟源医药集团股份有限公司独立董事 关于第五届董事会第九次会议相关事项发表的独立意见 根据《中华人民共和国公司法》、《关于在上市公司建立独立董事制度的指 导意见》、《深圳证券交易所上市公司自律监管指引第2号——创业板上市公司 规范运作》等法律、法规和规范性文件，以及《公司章程》和《独立董事工作制 度》等相关规定，作为山西仟源医药集团股份有限公司独立董事，基于独立判断 的立场，现就公司第五届董事会九次会议审议相关事项发表如下独立意见： 我们认为：公司本次变更部分募集资金投资项目之药品研发项目，符合整体 市场环境变化趋势以及公司的实际经营情况，有利于提高募集资金的使用率，增 强公司的核心竞争力。公司本次审议的相关决策程序符合《深圳证券交易所创业 板股票上市规则》、《深圳证券交易所上市公司自律监管指引第2号——创业板上 市公司规范运作》和《上市公司监管指引第2号—上市公司募集资金管理和使用 的监管要求》等相关法律、法规和规范性文件的要求，符合公司和全体股东的利 益，不存在损害公司及全体股东，尤其是中小股东利益的情形。因此，我们一致 同意公司变更部分募集资金投资项目之药品研发项目事宜。 ...

证券代码：300254 证券简称：仟源医药 公告编号：2023-071 山西仟源医药集团股份有限公司 关于公司盐酸舍曲林片通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 山西仟源医药集团股份有限公司（以下简称"公司"）近日收到了国家药品 监督管理局核准签发的"盐酸舍曲林片"的《药品补充申请批准通知书》，该药 品已通过仿制药质量与疗效一致性评价，现将相关情况公告如下： 一、药品基本情况 药品通用名称：盐酸舍曲林片 药品标准：YBH13312023 原药品批准文号：国药准字H20060316 英文名/拉丁名：Sertraline Hydrochloride Tablets 剂型：片剂 注册分类：化学药品 规格：50mg 公司盐酸舍曲林片用于治疗抑郁症的相关症状，包括伴随焦虑、有或无躁狂 史的抑郁症；也用于治疗强迫症。该品种现已列入国家医保目录。目前包括公司 在内已有5家企业通过仿制药质量和疗效一致性评价。 三、对公司的影响及风险提示 根据国家相关政策，通过仿制药质量与疗效一致性评价的药品品种，在药 品招标、医保支付层面等方面获得一定支持 ...

太平洋证券股份有限公司 关于山西仟源医药集团股份有限公司 2023 年半年度持续督导跟踪报告 | 保荐人名称：太平洋证券股份有限公司 | 被保荐公司简称：仟源医药 | | --- | --- | | 保荐代表人姓名：欧阳凌 | 联系电话：021-61376535 | | 保荐代表人姓名：杨竞 | 联系电话：010-88321518 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度的情况 | | | （1）是否督导公司建立健全规章制度（包括但不限于防止关联方 | | | 占用公司资源的制度、募集资金管理制度、内控制度、内部审计 | 是 | | 制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 6 次 | | （2）公司募集资金项目进展是否与信息披露文件一致 | 是 | | 4.公司治理督导 ...

证券代码： 300254 证券简称：仟源医药 山西仟源医药集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|---------------|----------------------------| | 投资者关系活动 | √特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | 参与单位名称及 人员姓名 三足基金：李功锋 时间 11:45-12:15 地点 公司上海办公室 上市公司接待人 员姓名 董秘：俞俊贤 1、公司连续亏损，今年从公司经营角度有没有好转的预 期？ 答：这几年公司受注射用美洛西林钠舒巴坦钠等重点产 品退出医保、部分产品未集采中标，计提金融负债财务费用、 计提各项资产减值准备等因素的影响，出现了连续亏损。随 着公司新产品的上市，计提金融负债财务费用的减少，闲置 投资者关系活动 资产出售等，未来公司经营业绩会有所改善。 主要内容介绍 2、公司财务费用较高的原因？ 答：公司这几年财务 ...

山西仟源医药集团股份有限公司2023年半年度报告全文 山西仟源医药集团股份有限公司 2023 年半年度报告 ...

证券代码：300254 证券简称：仟源医药 公告编号：2023-032 特此公告 山西仟源医药集团股份有限公司 董事会 山西仟源医药集团股份有限公司 关于参加山西辖区上市公司2023年 投资者网上集体接待日暨年报业绩说明会的公告 二〇二三年五月五日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，山西仟源医药集团股份有限公司（以下 简称"公司"）将参加由中国证券监督管理委员会山西监管局、山西省上市公司 协会与深圳市全景网络有限公司联合举办的"山西辖区上市公司 2023 年投资者 网上集体接待日暨年报业绩说明会活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP, 参与本次互动交流，活动时间为2023年5月11日（周四）15:00-17:00。 届时公司总裁赵群先生、董事会秘书俞俊贤先生、财务总监贺延捷先生以及 相关工作人员将在线就公司2022年度业绩、公司治理、发展战略、经营状况等投 资者关心的问题 ...

Financial Performance - The company's revenue for Q1 2023 was ¥183,185,038.02, a decrease of 4.46% compared to ¥191,735,280.29 in the same period last year[5] - The net loss attributable to shareholders was ¥2,156,812.13, representing a 40.00% increase in losses from ¥1,540,598.15 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 183,185,038.02, a decrease of 4.06% compared to CNY 191,735,280.29 in Q1 2022[23] - Net profit for Q1 2023 was CNY 2,981,088.59, a decline from CNY 3,850,295.44 in Q1 2022[24] - The total comprehensive income for the period was CNY 2,981,088.59, compared to CNY 3,850,295.44 in the previous period[25] - The company's basic and diluted earnings per share were both -¥0.0089, a decrease of 30.88% from -¥0.0068 in the same period last year[5] - The company reported a basic and diluted earnings per share of CNY -0.0089, compared to CNY -0.0068 in the previous period[25] Cash Flow and Liquidity - The net cash flow from operating activities was -¥6,564,702.62, a decline of 120.37% compared to a positive cash flow of ¥32,222,075.16 in the previous year[5] - The company reported a net cash flow from operating activities of CNY -6,564,702.62, a significant decrease from CNY 32,222,075.16 in the previous period[28] - Cash inflow from operating activities totaled CNY 195,669,573.00, down from CNY 237,810,837.66 year-over-year[27] - The balance of cash and cash equivalents at the end of the reporting period was ¥343,318,600, an increase of 30.07% due to the receipt of a ¥100,000,000 performance bond from asset sales[9] - The company reported a cash balance of CNY 343,318,562.95 as of March 31, 2023, up from CNY 263,945,639.30 at the beginning of the year, indicating a growth of approximately 30.1%[20] - Cash and cash equivalents at the end of the period amounted to CNY 341,918,562.95, an increase from CNY 114,720,149.01 at the end of the previous period[28] - The net cash flow from investing activities was CNY 94,530,117.73, a turnaround from CNY -8,937,432.09 in the previous period[28] - The total cash outflow from financing activities was CNY 10,892,491.46, compared to CNY 12,169,773.54 in the previous period[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,644,516,932.21, an increase of 3.80% from ¥1,584,324,080.78 at the end of the previous year[5] - The company's total assets increased to CNY 1,644,516,932.21 in Q1 2023, up from CNY 1,584,324,080.78 in Q1 2022[22] - Total liabilities rose to CNY 911,856,123.42 in Q1 2023, compared to CNY 854,644,360.58 in the previous year[22] - The balance of prepayments decreased by 39.02% to ¥13,088,600, primarily due to reduced advance payments for goods[9] - Other non-current assets increased by 142.45% to ¥2,246,200, mainly due to increased advance payments for long-term asset purchases[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,008[13] - The total number of restricted shares at the end of the period was 17,985,699, with no shares released during the reporting period[16] - The top ten unrestricted shareholders hold a total of 50,000,000 shares, with the largest shareholder holding 15,772,409 shares[14] Strategic Initiatives - The company completed the election of the fifth board of directors and management team, appointing key personnel including Huang Lequn as chairman and Zhao Qun as president[17] - The subsidiary Jiangsu Jiayi Pharmaceutical Co., Ltd. received drug registration certificates for two new products, indicating ongoing product development efforts[17] - The company signed an asset sale framework agreement with Shanxi Shuangyan Pharmaceutical Co., Ltd. to optimize asset structure and reduce operational costs[18] - The company’s subsidiary Sichuan Qianyuan Traditional Chinese Medicine Co., Ltd. received a high-tech enterprise certificate, enhancing its market position[18] - The company aims to centralize production to lower costs and improve profitability, aligning with its strategic goals[18] - The company’s financial strategy includes avoiding large-scale fixed asset investments while enhancing operational efficiency through asset optimization[18] Operating Costs and Expenses - Total operating costs for Q1 2023 were CNY 185,981,096.81, down 7.26% from CNY 200,523,656.60 in the same period last year[23] - The company reported a decrease in sales expenses to CNY 76,345,934.29 in Q1 2023, down from CNY 94,256,873.49 in Q1 2022[23] - Research and development expenses for Q1 2023 were CNY 8,927,664.99, a decrease of 5.5% from CNY 9,449,694.89 in Q1 2022[24]

Financial Performance - The net profit attributable to shareholders for the year was -118.5746 million yuan, primarily impacted by the failure of Ebastine tablets to win the national centralized procurement bid in Q4 2022, leading to a 10.9% year-over-year decline in operating revenue[5]. - The company's operating revenue for 2022 was ¥828,997,054.54, a decrease of 10.90% compared to ¥930,374,948.87 in 2021[24]. - The net profit attributable to shareholders was -¥118,574,644.28, representing a decline of 29.68% from -¥91,437,557.03 in the previous year[24]. - The cash flow from operating activities was ¥74,876,116.47, down 22.75% from ¥96,921,058.52 in 2021[24]. - The basic and diluted earnings per share were both -¥0.5002, a decrease of 24.71% from -¥0.4011 in 2021[24]. - The net cash flow from operating activities decreased by 22.75% to ¥74,876,116.47 compared to the previous year[65]. - The net cash flow from financing activities increased significantly by 173.91% to ¥112,563,796.19, primarily due to funds raised from a simplified refinancing process[65]. - The total cash and cash equivalents increased by 303.82% to ¥164,240,359.82, reflecting improved liquidity[65]. - The company reported a total distributable profit of 0.00 yuan, with no cash dividends or stock bonuses proposed for the 2022 fiscal year[142]. - The cash dividend amount, including other methods, was also reported as 0.00 yuan, indicating no distribution to shareholders[142]. Strategic Focus and Development - The company is focusing on the development of new products and technologies, although specific details were not provided in the report[5]. - The company is exploring potential mergers and acquisitions to enhance its market position, although no specific targets were disclosed[5]. - The company is committed to enhancing its research and development capabilities to meet the growing demand for health products and improve product competitiveness[35]. - The company aims to focus on high-end drug research and development, transitioning from generic drugs to high-quality generics, and plans to enhance its core competitiveness through increased R&D efforts[93]. - The company plans to enhance sales by focusing on new product launches and optimizing existing product strategies, with an emphasis on expanding the OTC market and improving online sales efficiency[94]. - The company plans to increase R&D efficiency and accelerate new product development, with a focus on high-difficulty generic projects and innovative drug research[94]. Market Environment and Challenges - The pharmaceutical industry faced a complex external environment in 2022, with a 1.6% decline in revenue and a 31.8% drop in total profit for the industry[33]. - The decline in revenue was primarily due to the failure of Ebasitine tablets to win the national centralized procurement bid, significantly impacting Q4 2022 results[40]. - The company continues to face uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profits over the last three years[24]. - The company faces risks from industry policy changes, including drug price reductions and potential exits from the National Medical Insurance Directory, which could significantly impact revenue[96][98]. - Rising raw material costs pose a risk, prompting the company to implement lean production practices to improve efficiency and reduce costs[99]. Governance and Compliance - The company strictly adheres to the requirements of the Company Law and relevant regulations, ensuring compliance in corporate governance and enhancing information disclosure practices[103]. - The board of directors has established four specialized committees, including the Innovation and Strategy Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee, to provide professional opinions for decision-making[104]. - The company has a complete and independent financial institution, with a robust accounting system and independent financial decision-making capabilities[109]. - The board approved the adjustment of the 2021 private placement plan for specific targets[125]. - The company emphasized the importance of considering the interests of minority shareholders in decision-making processes[129]. Human Resources and Talent Development - The total number of employees at the end of the reporting period was 1,217, including 458 at the parent company and 759 at major subsidiaries[135]. - The company emphasizes talent introduction and training, continuously improving training mechanisms to enhance employee skills[138]. - The company has established a salary policy that matches job value and performance, enhancing employee motivation and satisfaction[137]. - The company has 54 employees with a postgraduate degree or above, 340 with a bachelor's degree, 403 with a diploma, and 420 with a high school education or below[135]. Environmental Responsibility - The company strictly adheres to environmental protection laws and standards, confirming compliance with various national and local regulations[150]. - The company invested 1.2365 million yuan in environmental governance and protection in 2022[155]. - The concentration of ammonia nitrogen in wastewater was reduced to 458 mg/L, with a total discharge of 2 tons/year[152]. - The company has implemented an online monitoring system for chemical oxygen demand, ammonia nitrogen, flow, and pH at the wastewater discharge outlet[155]. - The company has established a comprehensive emergency response plan for environmental incidents, filed with the local ecological environment bureau[154]. Financial Management and Fundraising - The company raised RMB 110 million through a private placement of shares in May 2022, aimed at optimizing product structure and enhancing R&D capabilities[51]. - The company plans to use RMB 11,500 million from the 2020 fundraising to increase capital in its subsidiary, Qianyuan Baoling[78]. - The company has committed to invest RMB 25,000 million in various projects, with RMB 12,238 million already utilized by the end of the reporting period[81]. - The company has significant assets pledged for bank loans, totaling ¥710,563,168.94, indicating a reliance on external financing[72]. - The company has not made any major acquisitions or disposals of assets during the reporting period[172].